<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ixazomib, lenalidomide, and dexamethasone (IRd) for multiple myeloma&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ixazomib, lenalidomide, and dexamethasone (IRd) for multiple myeloma<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Ixazomib, lenalidomide, and dexamethasone (IRd) for multiple myeloma<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 28 days.</td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Ixazomib</td> <td>4 mg by mouth</td> <td>Take at least one hour prior to or two hours following a meal. Swallow capsule whole; do not break, open, or chew.</td> <td>Days 1, 8, and 15</td> </tr> <tr> <td>Lenalidomide*</td> <td>25 mg<sup>¶</sup> by mouth</td> <td>Take with water. Swallow capsule whole; do not break, open, or chew.</td> <td>Daily, on days 1 through 21</td> </tr> <tr class="divider_bottom"> <td>Dexamethasone</td> <td>40 mg<sup>¶</sup> by mouth</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>LOW (10 to 30% risk of emesis).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Antithrombotic prophylaxis</strong></td> <td colspan="3"> <ul> <li>Routine antithrombotic prophylaxis is warranted. The risk of thromboembolism was over 10% with another lenalidomide and high-dose dexamethasone (RD) regimen.<sup>[2]</sup></li> <li>Refer to UpToDate topics on thrombotic complications following treatment of multiple myeloma with immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Ixazomib: Reduce ixazomib dose to 3 mg orally on days 1, 8, and 15 in patients with moderate (total bilirubin &gt;1.5 to 3 times ULN) or severe (total bilirubin &gt;3 times ULN) hepatic impairment and in those with severe renal impairment (creatinine clearance &lt;30 mL/min) or end-stage kidney disease requiring dialysis. Since the drug is not dialyzable, it may be administered without regard to the timing of dialysis.</li> <li>Lenalidomide: Patients with renal insufficiency experience more neutropenia with lenalidomide. Dose adjustment is recommended for patients with CrCl &lt;60 mL/min. Studies have not been conducted in patients with hepatic impairment.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count at baseline, every seven days for the first two cycles, days 1 and 15 in cycle 3, and every 28 days thereafter.<sup>[3]</sup></li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Electrolytes, renal, and hepatic function at baseline and the start of each cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assessment for peripheral neuropathy and/or neuropathic pain at baseline and prior to the start of each cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs of hypovolemia secondary to diarrhea and/or vomiting prior to each cycle.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for rash prior to each cycle.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelosuppression</strong></td> <td colspan="3"> <ul> <li>A cycle of IRd should not be started unless the ANC is ≥1000/microL and the platelet count is ≥75,000/microL.<sup>[4]</sup> If platelets are &lt;30,000/microL and/or the ANC is &lt;500/microL, hold ixazomib and lenalidomide until platelet count is at least 30,000/mm<sup>3</sup> and the ANC is at least 500/mm<sup>3</sup>. Consider prophylactic G-CSF in subsequent cycles for those with ANC &lt;500/microL. Following recovery, reduce lenalidomide dose by 5 mg and resume ixazomib at its most recent dose.<sup>[3]</sup> If platelet count and/or ANC falls to this level again, withhold both ixazomib and lenalidomide. Following recovery, reduce ixazomib by one dose level (from 4 mg to 3 mg; from 3 mg to 2.3 mg) and resume lenalidomide at its most recent dose.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Rash</strong></td> <td colspan="3"> <ul> <li>If grade 2 or 3, withhold lenalidomide until rash recovers to grade 1 or lower. Following recovery, reduce lenalidomide dose by 5 mg. If grade 2 or 3 rash recurs, withhold lenalidomide and ixazomib. Following recovery to grade 1 or lower, resume ixazomib at next lower dose (from 4 mg to 3 mg; from 3 mg to 2.3 mg) and lenalidomide at its most recent dose. If grade 4 rash develops, discontinue treatment regimen.<sup>[3]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Peripheral neuropathy</strong></td> <td colspan="3"> <ul> <li>If grade 1 with pain or grade 2, withhold ixazomib until neuropathy recovers to grade 1 or lower without pain or patient's baseline, and resume ixazomib at its most recent dose. For grade 2 with pain or grade 3, withhold ixazomib until recovery to patient's baseline condition or grade 1 or lower, and resume ixazomib at a dose reduced by one dose level (from 4 mg to 3 mg; from 3 mg to 2.3 mg). For grade 4 peripheral neuropathy, discontinue treatment regimen.<sup>[4]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Thrombotic microangiopathy</strong></td> <td colspan="3"> <ul> <li>Rarely, ixazomib has been associated with TMA, which can present with Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings.<sup>[4]</sup> If TMA is suspected, stop ixazomib and evaluate.</li> <li>Refer to UpToDate topics on drug-induced thrombotic microangiopathy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Other nonhematologic toxicities</strong></td> <td colspan="3"> <ul> <li>If grade 3 or 4, withhold ixazomib and upon recovery to patient's baseline or grade 1 or lower, resume ixazomib at its most recent dose. If toxicity believed to be attributable to ixazomib, resume at next lower dose (from 4 mg to 3 mg; from 3 mg to 2.3 mg).</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">ULN: upper limit of normal; CrCl: creatinine clearance; CBC: complete blood count; ANC: absolute neutrophil count; G-CSF: granulocyte colony stimulating factor; TMA: thrombotic microangiopathy.<br/>
* In the United States, the use of lenalidomide is subject to the REVLIMID REMS Program (<a href="https://www.revlimidrems.com" target="_blank">www.revlimidrems.com</a>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.<br/>
¶ For frail older adult patients, we decrease the starting doses of lenalidomide (to 15 mg) and dexamethasone (to 20 mg). Following 9 to 12 months of therapy in this population, we transition to maintenance with single agent lenalidomide.</div><div class="graphic_reference">References:
<ol>
<li>Moreau P, et al. N Engl J Med 2016; 374:1621.</li>
<li>Rajkumar SV, et al. Lancet Oncol 2010; 11:29.</li>
<li>Lenalidomide capsules. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov/dailymed</a>, accessed on January 19, 2016.)</li>
<li>Ixazomib capsules. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov/dailymed</a>, accessed on March 4, 2020.)</li>
</ol></div><div id="graphicVersion">Graphic 106536 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
